BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-95@catalystbrief.girapphe.com
DTSTAMP:20261117T061558Z
LAST-MODIFIED:20261117T061558Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Readout: Novartis Pharmaceuticals — Inclisiran sodium 300 mg [May
  2027]
DESCRIPTION:Phase 3 primary completion: Study of Inclisiran to Prevent Card
 iovascular (CV) Events in Participants With Established Cardiovascular Dis
 ease.\nSource: https://clinicaltrials.gov/study/NCT05030428\nhttps://catal
 ystbrief.girapphe.com/e/95?lang=en\nNot investment advice. Dates may chang
 e.
URL:https://catalystbrief.girapphe.com/e/95?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
